Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Study With a Long-Term, Open-Label Extension to Evaluate the Efficacy and Safety of TRM-201 (Rofecoxib) in Patients With Hemophilic Arthropathy

NCT04684511 is registered in ClinicalTrials.gov with Tremeau Pharmceuticals, Inc. as lead sponsor.

NCT NCT04684511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04684511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Study With a Long-Term, Open-Label Extension to Evaluate the Efficacy and Safety of TRM-201 (Rofecoxib) in Patients With Hemophilic Arthropathy
Lead sponsor
Tremeau Pharmceuticals, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
June 2, 2021
Completion date
September 28, 2022
Enrollment
2 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilic arthropathy